Literature DB >> 3163362

Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia.

M L Christensen1, G K Rivera, W R Crom, M L Hancock, W E Evans.   

Abstract

Hydration and urinary alkalinization are used with high-dose methotrexate (HDMTX) to minimize renal toxicity resulting from methotrexate (MTX) precipitation in the kidney tubules. The effect of two hydration and alkalinization schedules on MTX plasma concentrations were evaluated in 100 children with acute lymphocytic leukemia (ALL) following two courses of MTX, 2 g/m2. The mean 21- and 44-hour MTX plasma concentrations were significantly lower in the group receiving the greater hydration and alkalinization schedule: 0.79 (0.90 SD) v 1.39 (1.99 SD) mumol/L for 21-hour MTX plasma concentrations, P = .01; and 0.18 (0.38 SD) v 0.25 (0.50 SD) mumol/L for 44-hour MTX plasma concentrations, P = .01. Although the overall incidence of toxic events was similar in both groups, the incidence of severe toxicity was reduced in the group that received the greater hydration and alkalinization, 6% v 16%. This study demonstrated that the amount of hydration and alkalinization can affect MTX plasma concentrations. Optimizing the hydration and alkalinization schedule is important for minimizing the incidence of severe toxicity associated with HDMTX.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3163362     DOI: 10.1200/JCO.1988.6.5.797

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.

Authors:  Silas W Smith; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2008-06

Review 2.  Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.

Authors:  E Masson; W C Zamboni
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

3.  Proteinuria due to suboptimal hydration with high-dose methotrexate therapy.

Authors:  G T Kovács; C Paál; P Somló; R Koós; D Schuler; J D Borsi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Disposition of antineoplastic agents in the very young child.

Authors:  H L McLeod; M V Relling; W R Crom; K Silverstein; S Groom; J H Rodman; G K Rivera; W M Crist; W E Evans
Journal:  Br J Cancer Suppl       Date:  1992-08

Review 5.  Fluid Stewardship of Maintenance Intravenous Fluids.

Authors:  John R Carr; W Anthony Hawkins; Andrea Sikora Newsome; Susan E Smith; Clemmons Amber B; Christopher M Bland; Trisha N Branan
Journal:  J Pharm Pract       Date:  2021-04-08

Review 6.  Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies).

Authors:  Carole Ichai; Christophe Vinsonneau; Bertrand Souweine; Fabien Armando; Emmanuel Canet; Christophe Clec'h; Jean-Michel Constantin; Michaël Darmon; Jacques Duranteau; Théophille Gaillot; Arnaud Garnier; Laurent Jacob; Olivier Joannes-Boyau; Laurent Juillard; Didier Journois; Alexandre Lautrette; Laurent Muller; Matthieu Legrand; Nicolas Lerolle; Thomas Rimmelé; Eric Rondeau; Fabienne Tamion; Yannick Walrave; Lionel Velly
Journal:  Ann Intensive Care       Date:  2016-05-27       Impact factor: 6.925

7.  Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia.

Authors:  Xiao Li; Zhongguo Sui; Fanbo Jing; Wen Xu; Xiangpeng Li; Qie Guo; Shuhong Sun; Xiaolin Bi
Journal:  Cancer Manag Res       Date:  2019-07-05       Impact factor: 3.989

8.  Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.

Authors:  Tetsuichiro Isono; Daiki Hira; Aya Morikochi; Tadateru Fukami; Satoshi Ueshima; Kazuhiko Nozaki; Tomohiro Terada; Shin-Ya Morita
Journal:  Pharmacol Res Perspect       Date:  2021-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.